Tekmira gets fast track designation for anti-Ebola therapeutic

Tekmira Pharmaceuticals Corporation, a developer of RNA interference therapeutics, announced on Wednesday that the U.S. Food and Drug Administration granted fast track designation for its anti-Ebola viral therapeutic.

The fast track designation for TKM-Ebola is meant to facilitate the development and expedite the review of the drug. The FDA gives the designation to drugs that treat serious conditions and fill an unmet medical need with the purpose of getting new drugs to patients earlier.

"This is an important milestone for Tekmira and our TKM-Ebola program," Mark Murray, the president and CEO of Tekmira, said. "Receiving a fast track designation from the FDA supports our work to advance the development of this therapeutic as quickly as possible. Our leadership in developing anti-viral therapies has been supported by our collaboration with the U.S. Department of Defense, which is funding the development of TKM-Ebola."

Murray said the company dosed the first subject in a Phase I clinical trial of TKM-Ebola in January. The trial is evaluating the safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult subjects. Tekmira seeks to have data from the trial available in the second half of 2014.

Tekmira is developing TKM-Ebola under a $140 million contract with the DoD's Medical Countermeasure Systems BioDefense Therapeutics Joint Product Management Office.

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.